The following adverse reactions are described elsewhere in the labeling:
1. Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers
2. Central Nervous System Effects
3. Hyperlipidemia
4. Atrioventricular Block
5. Interstitial Lung Disease/Pneumonitis
6. Hypertension
7. Hyperglycemia
FDA,2021.03